BOTHELL, Wash., Sept. 3, 2019 /PRNewswire/
-- BioLife Solutions, Inc. (NASDAQ:
BLFS), a leading developer and supplier of a portfolio of
best-in-class bioproduction tools for cell and gene therapies,
today announced that Mustang Bio, Inc. (NASDAQ: MBIO), a
clinical-stage biopharmaceutical company focused on translating
today's medical breakthroughs in cell and gene therapies into
potential cures for hematologic cancers, solid tumors and rare
genetic diseases, has adopted BioLife's CryoStor cell freeze media
and evo cold chain system for use in current and upcoming clinical
trials.
After rigorous evaluations of various alternatives on the
market, Mustang selected BioLife's proprietary CryoStor and evo
products to support best biopreservation practices, which focus on
maximizing manufacturing yield and quality while reducing
distribution-related risks, such as temperature excursions and
in-transit shipping damage. The evo cold chain system was added to
BioLife's product portfolio via the recently announced acquisition
of SAVSU Technologies.
Mike Rice, BioLife's CEO,
remarked, "We appreciate the opportunity to support Mustang's
clinical programs. Our growing product portfolio is comprised of
tools that can reduce the risk of delivering a non-viable dose, and
the resulting therapeutic failure and economic loss for cell and
gene therapy developers."
About BioLife Solutions
BioLife Solutions is a leading supplier of cell and gene therapy
tools. Our proprietary CryoStor® freeze media and
HypoThermosol® shipping and storage media are
highly valued in the regenerative medicine, biobanking and drug
discovery markets. These biopreservation media products are
serum-free and protein-free, fully defined, and are formulated to
reduce preservation-induced cell damage and death. Our recently
acquired ThawStar® family of automated cell thawing
products and evo cold chain management system reduce therapeutic
and economic risk for cell and gene therapy developers by reducing
the potential of administering a non-viable dose. For more
information please visit www.biolifesolutions.com, and follow
BioLife on Twitter.
Cautions Regarding Forward Looking Statements
Except for historical information contained herein, this
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
statements concerning the company's anticipated future growth
strategy, including the acquisition of synergistic cell and gene
therapy manufacturing tools and services or technologies,
anticipated business and operations, guidance for financial results
in 2019, including achieving adjusted operating profit, adjusted
net income, EBITDA, adjusted EBITDA and cash flow from operations,
the potential utility of and market for our products and services,
potential revenue growth and market expansion, regulatory approvals
and/or commercial manufacturing of our customers' products, and
potential customer revenue. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking
statements, including among other things, uncertainty regarding
market adoption of products; uncertainty regarding third-party
market projections; market volatility; competition; litigation; and
those other factors described in our risk factors set forth in our
filings with the Securities and Exchange Commission from time to
time, including our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. We undertake no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be
required by applicable law.
Media & Investor Relations
Roderick de Greef
Chief Financial Officer
(425) 402-1400
rdegreef@biolifesolutions.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mustang-bio-adopts-cryostor-freeze-media-and-evo-cold-chain-system-for-cell-and-gene-therapy-manufacturing-and-distribution-300909513.html
SOURCE BioLife Solutions, Inc.